CMC Biologics and OnoSynergy form an agreement from cell-line development.
CMC Biologics and OncoSynergy have entered into an agreement for cell-line development, process development, analytical development, and manufacturing of non-GMP material to enable early toxicology testing and cGMP material for investigational new drug enabling toxicology studies and Phase I clinical trials. This work will advance OncoSynergy’s OS2966 monoclonal antibody program based on its “targeted synergy” approach–a strategy allowing broad inhibition of multiple fundamental cancer-growth mechanisms with a single drug. The project will be executed by CMC Biologics at its Copenhagen development and manufacturing facility. OncoSynergy EU SAS in France will lead the project.
Source: CMC Biologics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.